Internal Medicine, Endocrinology, Diabetes, & Metabolism · Greensburg, PA
NPI
1457458168
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
540 South St, Suite 306
Greensburg, PA, 15601
Phone (724) 832-3130
Groups this clinician bills Medicare through
Medicare paid, 2024
$166K
2,350 services
Medicare patients, 2024
796
Average age 72
Drug cost, 2024
$8.5M
18,667 prescriptions
Company payments, 2025
$82K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stephan Kowalyk was code 99214 (office e&m - established), 823 times for 478 patients. In total Stephan Kowalyk billed 2,350 services in 13 codes, and Medicare paid $166K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-01-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 823 | 478 | $85.85 | $71K |
| 99232 Hospital E&M - Subsequent | Facility | 604 | 123 | $54.09 | $33K |
| 95251 Test - Miscellaneous | Office | 264 | 146 | $23.82 | $6,287 |
| 99233 Hospital E&M - Subsequent | Facility | 204 | 53 | $81.32 | $17K |
| 99213 Office E&M - Established | Office | 168 | 159 | $57.64 | $9,683 |
| 99223 Hospital E&M - Initial | Facility | 143 | 126 | $118.73 | $17K |
| 99203 Office E&M - New | Office | 40 | 40 | $74.37 | $2,975 |
| 99309 SNF E&M | Facility | 35 | 11 | $73.99 | $2,590 |
| 99204 Office E&M - New | Office | 26 | 26 | $114.58 | $2,979 |
| 99215 Office E&M - Established | Office | 16 | 13 | $124.04 | $1,985 |
| 10005 Other Organ Systems | Office | 13 | 12 | $91.13 | $1,185 |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $89.79 | $1,077 |
By year: 2022 $198K for 2,462 services; 2023 $159K for 1,998 services; 2024 $166K for 2,350 services.
Medicare prescription drug claims, 2024
In 2024, the drug Stephan Kowalyk prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,983 prescriptions and refills. In total Stephan Kowalyk wrote 18,667 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,983 | 2,492 | 348 | $2.3M |
| Levothyroxine Sodium Generic | 1,678 | 3,521 | 364 | $15K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 1,020 | 1,233 | 184 | $1.1M |
| Jardiance Empagliflozin | 902 | 1,489 | 174 | $844K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 769 | 1,162 | 194 | $100K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 640 | 1,367 | 220 | $46K |
| Metformin Hcl Generic | 588 | 1,342 | 145 | $4,126 |
| Mounjaro Tirzepatide | 492 | 560 | 96 | $569K |
| Metformin Hcl Er Metformin Hcl | 476 | 983 | 102 | $6,627 |
| Synthroid Levothyroxine Sodium | 452 | 979 | 99 | $25K |
| Methimazole Generic | 416 | 638 | 81 | $2,173 |
| Farxiga Dapagliflozin Propanediol | 382 | 596 | 70 | $313K |
| Humalog Kwikpen U-100 Insulin Lispro | 341 | 457 | 89 | $87K |
| Trulicity Dulaglutide | 333 | 377 | 68 | $353K |
| Pioglitazone Hcl Generic | 304 | 552 | 60 | $3,113 |
Brand drugs: 10,407 claims; generic drugs: 6,350 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stephan Kowalyk $82K ($82K in general payments such as food, travel and fees) from 33 companies. The largest payer was Novo Nordisk Inc with $22K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 41 | $22K |
| Dexcom, Inc. DXCM | 28 | $18K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 18 | $15K |
| Lilly USA, LLC LLY | 26 | $13K |
| CeQur Corporation | 2 | $3,947 |
| Abbott Laboratories ABT | 17 | $3,798 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $2,787 |
| Amgen Inc. AMGN | 23 | $293 |
| Mannkind Corporation MNKD | 13 | $237 |
| Medtronic, Inc. MDT | 17 | $223 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.